The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective hematopoiesis and a wide spectrum of manifestations ranging from indolent and asymptomatic cytopenias to acute myeloid leukemia (AML). MDS result from genetic and epigenetic derangements in clonal cell...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2018/2458679 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849684830445371392 |
|---|---|
| author | Nora Chokr Rima Patel Kapil Wattamwar Samer Chokr |
| author_facet | Nora Chokr Rima Patel Kapil Wattamwar Samer Chokr |
| author_sort | Nora Chokr |
| collection | DOAJ |
| description | Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective hematopoiesis and a wide spectrum of manifestations ranging from indolent and asymptomatic cytopenias to acute myeloid leukemia (AML). MDS result from genetic and epigenetic derangements in clonal cells and their surrounding microenvironments. Studies have shown associations between MDS and other autoimmune diseases. Several immune mechanisms have been identified in MDS, suggesting that immune dysregulation might be at least partially implicated in its pathogenesis. This has led to rigorous investigations on the role of immunomodulatory drugs as potential treatment options. Epigenetic modification via immune check point inhibition, while well established as a treatment method for advanced solid tumors, is a new approach being considered in hematologic malignancies including high risk MDS. Several trials are looking at the efficacy of these agents in MDS, as frontline therapy and in relapse, both as monotherapy and in combination with other drugs. In this review, we explore the utility of immune checkpoint inhibitors in MDS and current research evaluating their efficacy. |
| format | Article |
| id | doaj-art-bd3b53acfef940e8b0d428a6cf056560 |
| institution | DOAJ |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-bd3b53acfef940e8b0d428a6cf0565602025-08-20T03:23:19ZengWileyAdvances in Hematology1687-91041687-91122018-01-01201810.1155/2018/24586792458679The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic SyndromesNora Chokr0Rima Patel1Kapil Wattamwar2Samer Chokr3Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USATufts Medical Center, Boston, MA, USADepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USAMedical University of Varna, Varna, BulgariaMyelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective hematopoiesis and a wide spectrum of manifestations ranging from indolent and asymptomatic cytopenias to acute myeloid leukemia (AML). MDS result from genetic and epigenetic derangements in clonal cells and their surrounding microenvironments. Studies have shown associations between MDS and other autoimmune diseases. Several immune mechanisms have been identified in MDS, suggesting that immune dysregulation might be at least partially implicated in its pathogenesis. This has led to rigorous investigations on the role of immunomodulatory drugs as potential treatment options. Epigenetic modification via immune check point inhibition, while well established as a treatment method for advanced solid tumors, is a new approach being considered in hematologic malignancies including high risk MDS. Several trials are looking at the efficacy of these agents in MDS, as frontline therapy and in relapse, both as monotherapy and in combination with other drugs. In this review, we explore the utility of immune checkpoint inhibitors in MDS and current research evaluating their efficacy.http://dx.doi.org/10.1155/2018/2458679 |
| spellingShingle | Nora Chokr Rima Patel Kapil Wattamwar Samer Chokr The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes Advances in Hematology |
| title | The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes |
| title_full | The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes |
| title_fullStr | The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes |
| title_full_unstemmed | The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes |
| title_short | The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes |
| title_sort | rising era of immune checkpoint inhibitors in myelodysplastic syndromes |
| url | http://dx.doi.org/10.1155/2018/2458679 |
| work_keys_str_mv | AT norachokr therisingeraofimmunecheckpointinhibitorsinmyelodysplasticsyndromes AT rimapatel therisingeraofimmunecheckpointinhibitorsinmyelodysplasticsyndromes AT kapilwattamwar therisingeraofimmunecheckpointinhibitorsinmyelodysplasticsyndromes AT samerchokr therisingeraofimmunecheckpointinhibitorsinmyelodysplasticsyndromes AT norachokr risingeraofimmunecheckpointinhibitorsinmyelodysplasticsyndromes AT rimapatel risingeraofimmunecheckpointinhibitorsinmyelodysplasticsyndromes AT kapilwattamwar risingeraofimmunecheckpointinhibitorsinmyelodysplasticsyndromes AT samerchokr risingeraofimmunecheckpointinhibitorsinmyelodysplasticsyndromes |